8-K: 180 Life Sciences Corp. Announces Share Repurchase Agreement with Elray Resources and Luxor Capital

180 Life Sciences Corp. has entered into a Settlement and Mutual Release Agreement with Elray Resources, Inc. and Luxor Capital, LLC to repurchase 1,318,000 shares of its common stock, simplifying its capital structure.

Summary

• 180 Life Sciences Corp. (ATNF) announced a Settlement and Mutual Release Agreement with Elray Resources, Inc. and Luxor Capital, LLC on April 28, 2025.
• The agreement involves the repurchase of 1,318,000 shares of ATNF common stock held by Elray, representing approximately 23.1% of the company's outstanding shares.
• The repurchase price is $1 million, with $350,000 paid to Elray and $650,000 to Luxor, payable from future capital raises by April 28, 2026.
• Elray and Luxor are controlled by Anthony Brian Goodman, the father of ATNF director Jay Goodman.
• Elray has agreed to a Voting Agreement, voting any remaining shares as recommended by the Board until April 28, 2026, enforced by an irrevocable proxy to CEO Blair Jordan.
• The agreement includes mutual releases of claims and an indemnity from Luxor against certain third-party claims.
• The company believes this repurchase will reduce dilution and simplify its capital structure, allowing it to focus on monetizing its Technology Gaming Platform.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the share repurchase and simplification of the capital structure. However, the pivot to iGaming and reliance on future capital raises introduce significant risks.

Positives

• The share repurchase simplifies the company's capital structure.
• The repurchase reduces potential dilution for existing shareholders.
• The payment structure allows the company to preserve immediate cash liquidity for operations and R&D.
• The company secures an indemnity from Luxor against certain third-party claims.
• The Voting Agreement ensures Elray will vote in line with the Board's recommendations.

Negatives

• The company is paying a premium of $1 million to repurchase shares that were issued upon conversion of preferred stock.
• The Luxor payment is contingent on future capital raises, potentially creating pressure to raise capital.
• The company is pivoting to the iGaming sector, which may be outside its core expertise.
• The company is reliant on future capital raises to complete the settlement payments.

Risks

• The company's ability to raise future capital to pay Luxor is uncertain.
• The company's success in the iGaming sector is not guaranteed and depends on acquiring or developing successful online casino businesses.
• The company faces competition in the iGaming industry.
• The company is exposed to risks related to fraud, theft, or cheating in the iGaming sector.
• The company's ability to obtain and maintain licenses for iGaming is uncertain.

Future Outlook

The company plans to monetize its Technology Gaming Platform by evaluating potential acquisitions of one or more operating online casinos. The company expects the share repurchase to reduce dilution and simplify its capital structure.

Management Comments

• Blair Jordan, Chief Executive Officer of 180 Life Sciences, stated that the share repurchase represents a positive step forward for stockholders by reducing dilution and simplifying the capital structure.
• Blair Jordan also mentioned that the company appreciates the cooperation of Elray and Luxor in reaching a resolution that allows them to move forward with greater clarity and focus on monetizing the Technology Gaming Platform.

Industry Context

180 Life Sciences is pivoting from biotechnology to the global iGaming sector, indicating a strategic shift to capitalize on the growing online casino market. This move positions the company to compete with established iGaming operators and requires expertise in online casino operations, licensing, and technology.

Comparison to Industry Standards

• Share repurchases are a common method for companies to return value to shareholders, but the premium paid in this case may raise concerns.
• The company's pivot to iGaming is a significant strategic shift, requiring substantial investment and expertise to compete with established players like Flutter Entertainment (Flutter), Evolution Gaming, and Entain.
• The success of the company's iGaming venture will depend on its ability to acquire or develop a competitive online casino platform and secure necessary licenses.
• The company's reliance on future capital raises to fund the Luxor payment is a potential risk, as it may be difficult to secure favorable terms in the current market.

Related Party Transactions

• The settlement agreement involves Elray Resources and Luxor Capital, both controlled by Anthony Brian Goodman, the father of 180 Life Sciences director Jay Goodman.
• Jay Goodman abstained from the Board of Directors' vote on the Settlement Agreement.

Stakeholder Impact

• Shareholders may benefit from the reduced dilution and simplified capital structure.
• The company's employees may be affected by the strategic shift to iGaming.
• The company's suppliers and creditors may be affected by the company's financial performance in the iGaming sector.

Next Steps

• The company will make the initial $350,000 payment to Elray within five business days.
• The company will seek to raise capital to fund the $650,000 payment to Luxor.
• The company will evaluate potential acquisitions of one or more operating online casinos.
• Elray Shares will be returned to the Company and cancelled, significantly reducing the Company's outstanding share count to the benefit of stockholders.

Key Dates

Keywords

share repurchase, settlement agreement, capital structure, iGaming, online casino, voting agreement, dilution, ATNF, 180 Life Sciences, Elray Resources, Luxor Capital